Abstract
Schizophrenia is a chronic and debilitating brain disorder. It is associated with increased mortality, primarily due to elevated cardio-metabolic risk. Affected patients have higher rates of obesity, metabolic syndrome and diabetes [1]. Intrinsic factors contributing to this increased risk include a shared underlying pathophysiology between schizophrenia and diabetes mellitus involving stress, inflammation and genetics. Extrinsic contributing factors include diet, lifestyle, health care access, low socioeconomic status and overburden of traditional diabetes risk factors. Antipsychotics are associated with an increased risk of obesity, metabolic syndrome and diabetes mellitus [1]. Appetite-regulating hormones, pharmacodynamics and alterations in glucose metabolism may underlie the negative effect of these medications. Reduction in diabetes risk is achieved by mitigating traditional risk factors. Non-pharmacologic and pharmacologic approaches to cardio-metabolic risk reduction may be helpful in these patients.
Keywords: Antipsychotics, diabetes mellitus, metabolic syndrome, obesity, schizophrenia.
Current Diabetes Reviews
Title:The Complex Inter-Relationship Between Diabetes and Schizophrenia
Volume: 13 Issue: 3
Author(s): Jeffrey Rado*
Affiliation:
- Department of Psychiatry and General Internal Medicine, Northwestern University, Chicago, IL,United States
Keywords: Antipsychotics, diabetes mellitus, metabolic syndrome, obesity, schizophrenia.
Abstract: Schizophrenia is a chronic and debilitating brain disorder. It is associated with increased mortality, primarily due to elevated cardio-metabolic risk. Affected patients have higher rates of obesity, metabolic syndrome and diabetes [1]. Intrinsic factors contributing to this increased risk include a shared underlying pathophysiology between schizophrenia and diabetes mellitus involving stress, inflammation and genetics. Extrinsic contributing factors include diet, lifestyle, health care access, low socioeconomic status and overburden of traditional diabetes risk factors. Antipsychotics are associated with an increased risk of obesity, metabolic syndrome and diabetes mellitus [1]. Appetite-regulating hormones, pharmacodynamics and alterations in glucose metabolism may underlie the negative effect of these medications. Reduction in diabetes risk is achieved by mitigating traditional risk factors. Non-pharmacologic and pharmacologic approaches to cardio-metabolic risk reduction may be helpful in these patients.
Export Options
About this article
Cite this article as:
Rado Jeffrey*, The Complex Inter-Relationship Between Diabetes and Schizophrenia, Current Diabetes Reviews 2017; 13 (3) . https://dx.doi.org/10.2174/1573399812666161220144740
DOI https://dx.doi.org/10.2174/1573399812666161220144740 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews Type 2 Diabetes and Asthma: Systematic Review of the Bidirectional Relationship
Current Diabetes Reviews Nature and Nurture in the Early-Life Origins of Metabolic Syndrome
Current Pharmaceutical Biotechnology Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Current Diabetes Reviews Drug Delivery Systems for the Treatment of Diabetes Mellitus: State of the Art
Current Pharmaceutical Design The Role of Diabetes Mellitus in Diseases of the Gallbladder and Biliary Tract
Current Diabetes Reviews Chronic Latent Magnesium Deficiency in Obesity Decreases Positive Effects of Vitamin D on Cardiometabolic Risk Indicators
Current Vascular Pharmacology A Review on the Phytochemicals, Ethnomedicine Uses and Pharmacology of Ficus Species
Current Traditional Medicine Molecular Mechanisms of Diabetic Nephropathy and Its Therapeutic Intervention
Current Drug Targets QSAR Studies of PTP1B Inhibitors: 1, 2-Naphthoquinone Derivatives
Letters in Drug Design & Discovery The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism Diet and Metabolic Syndrome: An Overview
Current Vascular Pharmacology Weight Loss Following Roux-en-Y Gastric Bypass Surgery: A Systematic Review of Psychosocial Predictors
Current Psychiatry Reviews The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research Blood Pressure and White Matter Lesions in Patients with Vascular Disease: The SMART-MR Study
Current Neurovascular Research Diet and Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Breast Cancer: Biological Characteristics in Postmenopausal Type 2 Diabetic Women. Identification of Therapeutic Targets
Current Drug Targets - Immune, Endocrine & Metabolic Disorders L-/N-type Calcium Channel Blockers and Proteinuria
Current Hypertension Reviews Atherosclerosis-Related Functions of C-Reactive Protein
Cardiovascular & Hematological Disorders-Drug Targets Peroxynitrite-Driven Mechanisms in Diabetes and Insulin Resistance – the Latest Advances
Current Medicinal Chemistry